文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

ROX指数在高流量鼻导管氧疗患者中的早期临床应用与预测

[Early clinical application and prediction of ROX index in patients with high-flow nasal canula oxygen therapy].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2023-01-01
一句话结论高流量鼻导管氧疗6小时ROX指数对疗效有预测价值,最佳截断值8.78,敏感度90.6%、特异度76.5%。

该回顾性队列研究纳入2020年4月至2022年8月天津市第三中心医院重症医学科收治的Ⅰ型呼吸衰竭、常规氧疗失败后接受高流量鼻导管氧疗(HFNC)的142例患者,其中HFNC成功96例(67.61%),失败46例(32.39%),总插管率4.93%(7/142)。HFNC失败组2、4、6、8、10、12小时ROX指数均显著低于成功组(均P<0.05),初始ROX指数两组无统计学差异。ROC曲线分析显示6、8、10小时ROX指数评估HFNC疗效的AUC分别为0.890、0.903、0.930,优于2、4、12小时的0.585、0.738、0.829;最佳截断值8.78时敏感度90.6%、特异度76.5%。作者认为6小时ROX指数对HFNC疗效有一定预测价值,可为临床医护人员观察HFNC疗效、早期正确选择氧疗方式及及时调整氧疗策略提供方法。

要点

  • HFNC失败组6小时ROX指数为7.62±1.65,显著低于成功组的11.85±3.45(P<0.05)。
  • 6、8、10小时ROX指数评估HFNC疗效的AUC分别为0.890、0.903、0.930,优于2、4、12小时的0.585、0.738、0.829。
  • ROX指数最佳截断值8.78时,预测HFNC失败的敏感度90.6%、特异度76.5%。
  • HFNC失败组12小时内升级氧疗者12例(26.09%),其中6小时内3例(6.52%),6小时后9例(19.57%)。
  • HFNC失败组PaO2/FiO2低于成功组(208.8±37.3 vs. 235.7±48.3 mmHg,P<0.01),初始气流量高于成功组(46.4±3.9 vs. 42.3±4.9 L/min,P<0.01)。

适用人群与场景

  • 天津市第三中心医院重症医学科2020年4月至2022年8月收治的Ⅰ型呼吸衰竭患者。
  • 常规氧疗失败后接受HFNC治疗的患者。

诊断标准与关键阈值

  • HFNC成功:HFNC治疗后症状及PaO2/FiO2改善,且后续未使用更高呼吸支持。
  • HFNC失败:症状恶化,需后续无创正压通气(NIPPV)或有创正压通气(IPPV)。
  • ROX指数预测HFNC失败的最佳截断值为8.78,敏感度90.6%、特异度76.5%。

研究设计与关键结果

  • 回顾性队列研究,最终纳入142例,HFNC成功96例(67.61%),失败46例(32.39%),其中接受NIPPV 39例、IPPV 7例,总插管率4.93%(7/142)。
  • HFNC失败组PaO2/FiO2低于成功组(208.8±37.3 vs. 235.7±48.3 mmHg,P<0.01),初始气流量高于成功组(46.4±3.9 vs. 42.3±4.9 L/min,P<0.01);性别、年龄、原发诊断、疾病严重程度、血红蛋白、C反应蛋白、脑钠肽两组差异无统计学意义。
  • HFNC失败组12小时内升级氧疗12例(26.09%),其中6小时内3例(6.52%),6小时后9例(19.57%)。
  • 初始ROX指数两组差异无统计学意义;两组ROX指数随HFNC治疗时间延长均持续升高,失败组各时间点均显著低于成功组(2小时:9.39±2.85 vs. 10.91±3.51,4小时:8.62±2.29 vs. 11.40±3.18,6小时:7.62±1.65 vs. 11.85±3.45,8小时:7.79±1.59 vs. 11.62±3.10,10小时:7.97±1.62 vs. 12.44±2.75,12小时:8.84±2.51 vs. 12.45±3.03,均P<0.05)。
  • ROC曲线分析显示6、8、10小时ROX指数评估HFNC疗效的AUC分别为0.890、0.903、0.930,优于2、4、12小时的0.585、0.738、0.829,提示ROX指数可在HFNC早期(6小时内)判断疗效。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为6小时ROX指数对HFNC疗效有一定预测价值,最佳截断值8.78,可为临床医护人员提供观察HFNC疗效的方法,指导早期正确选择氧疗方式并及时调整氧疗策略。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To investigate the application value of ROX index in evaluating the effect of high-flow nasal cannula oxygen therapy (HFNC) on patients diagnosed with respiratory failure, and to find a simpler and more effective method to observe the efficacy of HFNC.

METHODS: A retrospective cohort study was conducted. Patients who were admitted to department of critical care medicine of the Tianjin Third Central Hospital from April 2020 to August 2022, diagnosed with type I respiratory failure, and treated with HFNC after failure of conventional oxygen therapy were enrolled. Oxygenation index (PaO2/FiO2), fraction of inspired oxygen (FiO2), gas flow rate at the initial time of admission, and pulse oxygen saturation (SpO2), FiO2 and respiratory rate (RR) at 2, 4, 6, 8, 10 and 12 hours of HFNC were collected, and ROX index was calculated. The patients with symptoms and PaO2/FiO2 improved after HFNC treatment and without higher respiratory support lately were defined as HFNC success, while other patients with symptoms worsening and needing follow-up non-invasive positive pressure ventilation (NIPPV) or invasive positive pressure ventilation (IPPV) were defined as HFNC failure. The tendency of changes in the ROX index at each time point was observed. Receiver operator characteristic curve (ROC curve) was plotted to obtain the optimum cut-off value of ROX index for predicting HFNC outcome and the optimal monitoring time point for HFNC.

RESULTS: A total of 142 patients were eventually enrolled, among whom 96 patients (67.61%) were in treated with HFNC successfully, while 46 patients (32.39%) were recorded as HFNC failure (39 patients and 7 patients received NIPPV or IPPV, respectively), with an overall intubation rate of 4.93% (7/142). Compared with the HFNC success group, the HFNC failure group had lower PaO2/FiO2 [mmHg (1 mmHg ≈ 0.133 kPa): 208.8±37.3 vs. 235.7±48.3, P < 0.01] and higher initial gas flow rate (L/min: 46.4±3.9 vs. 42.3±4.9, P < 0.01). However, there was no significant difference in gender, age, primary diagnosis, severity of disease, hemoglobin (Hb), C-reactive protein (CRP), and brain natriuretic peptide (BNP) between the two groups. In the HFNC failure group, there were 12 patients (26.09%) received progressive oxygen therapy within 12 hours of HFNC, of which 3 patients (6.52%) occurred within 6 hours, while the other 9 patients (19.57%) occurred after 6 hours. The initial ROX index was not statistically significant between the two groups. Both groups showed a continuous increasing ROX index with longer treatment duration of HFNC, and the ROX index at all of the time points of the HFNC failure group was significantly lower than that of the HFNC success group with statistically significant difference (2 hours: 9.39±2.85 vs. 10.91±3.51, 4 hours: 8.62±2.29 vs. 11.40±3.18, 6 hours: 7.62±1.65 vs. 11.85±3.45, 8 hours: 7.79±1.59 vs. 11.62±3.10, 10 hours: 7.97±1.62 vs. 12.44±2.75, 12 hours: 8.84±2.51 vs. 12.45±3.03, all P < 0.05). The ROC curve analysis showed that the areas under the ROC curve (AUC) of ROX index assessing the effect of HFNC at the time of treating 6, 8 and 10 hours were better than 2, 4 and 12 hours (0.890, 0.903, 0.930 vs. 0.585, 0.738 and 0.829), indicating that the ROX index could determine the efficacy at the early stage of HFNC (within 6 hours). When the optimum cut-off value of ROX index was 8.78, the sensitivity was 90.6%, and the specificity was 76.5%.

CONCLUSIONS: The ROX index at 6 hours of HFNC has a certain predictive value for the efficacy of HFNC with an optimum cut-off value of 8.78, which can provide clinical health care personnel a method for observing the efficacy of HFNC, and guide the correct selection of oxygen therapy modality at an early stage and timely adjustment of oxygen therapy strategy.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Liu Y, Xu C, Huang Y, et al. [Early clinical application and prediction of ROX index in patients with high-flow nasal canula oxygen therapy]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2023. PMID: 37593860. doi:10.3760/cma.j.cn121430-20221229-01127

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。